Pre-clinical in vivo gene therapy has shown promising results in a mouse model of ALD where intrathecal delivery of AAV9-ABCD1 in mice improved VLCFA metabolism and behavioral parameters (Gong et al., 2015). The gene discussed is ABCD1; the disease is X-linked adrenoleukodystrophy.